The Dr. Hyman Show

The Cardiologist Who Stopped Prescribing Statins Explains the Real Cause of Heart Attacks | Dr. Aseem Malhotra - ENCORE

December 24, 2025

Key Takeaways Copied to clipboard!

  • The legal vindication of Dr. Aseem Malhotra's colleagues against the *Mail on Sunday* highlights the intense conflict between critics of mainstream cardiovascular dogma and powerful industry/media interests, which led to Dr. Malhotra losing his NHS job. 
  • The prevailing medical paradigm overemphasizes lowering LDL cholesterol via statins, despite evidence suggesting that chronic inflammation and insulin resistance are the true drivers of heart disease, and that statins offer minimal benefit (NNT of 89 over five years for primary prevention). 
  • Medical knowledge is largely under commercial control, as funding from drug manufacturers biases scientific research and training, leading well-intentioned doctors to rely on incomplete or corrupted information regarding drug efficacy and safety, such as the fact that most published research findings may be false. 
  • Heart attacks are strongly correlated with an atherogenic lipid profile (low HDL and high triglycerides, often caused by sugar and starch) rather than solely high LDL cholesterol. 
  • Statins may offer no benefit to cardiovascular outcomes in patients with normal triglycerides and HDL, and their reported benefits often mask high rates of side effects like muscle pain and brain fog, leading to high discontinuation rates. 
  • The medical system is heavily influenced by commercial interests (Big Pharma and Big Food), leading to flawed science, dogma, and the underreporting of drug side effects, necessitating a shift toward ethical, evidence-based practice and shared decision-making. 

Segments

Defamation Lawsuit Context
Copied to clipboard!
(00:00:00)
  • Key Takeaway: Dr. Malhotra’s colleagues successfully sued the Mail on Sunday over articles labeling them ‘statin deniers,’ vindicating their concerns about statin data flaws.
  • Summary: The lawsuit involved articles from March 2019 that accused claimants of spreading ‘deadly propaganda’ about statins. The High Court ruled in favor of the colleagues against Associated Newspapers in 2024, supporting their defense of public interest regarding statin concerns. Dr. Malhotra chose not to sue personally but noted the article led to him losing his NHS job shortly after.
Financial Bias in Research
Copied to clipboard!
(00:09:49)
  • Key Takeaway: The newspaper’s attack was fueled by individuals connected to the Cholesterol Treatment Trialists’ Collaboration (CTT), whose institution receives hundreds of millions from drug companies.
  • Summary: The CTT is identified as a powerful group of statin promoters in medical research with significant financial ties to statin manufacturers. This illustrates how financial conflicts of interest can influence published research and shape public narratives, as funding dictates what is studied, often prioritizing drugs over lifestyle interventions. Professor John Ioannidis’s work suggests that financial prejudice is a major risk factor for false research findings.
Evidence-Based Medicine Triad
Copied to clipboard!
(00:19:14)
  • Key Takeaway: True evidence-based medicine requires balancing the best available evidence with clinical experience and individual patient preferences, which is often ignored when medical knowledge is under commercial control.
  • Summary: The evidence-based medicine triad emphasizes clinical expertise, best evidence, and patient values for optimal outcomes. When evidence is biased by industry funding, doctors make decisions based on corrupted information, exaggerating drug benefits and safety. This systemic issue leads to suboptimal patient outcomes and contributes to the chronic disease pandemic by overemphasizing LDL cholesterol.
Statin Efficacy and Mortality Data
Copied to clipboard!
(00:24:00)
  • Key Takeaway: Reduced cardiovascular mortality rates are primarily due to smoking reduction, better acute emergency treatments (stenting), and defibrillators, not statin use, which showed zero change in mortality across millions of European users.
  • Summary: A BMJ paper analyzing millions of Europeans over a decade found no reduction in cardiovascular mortality despite increased statin use. For secondary prevention (after a heart attack), the median life expectancy increase from statins is only about four days over five years. For primary prevention in low-risk groups, the benefit is preventing one non-fatal heart attack in 100 people over five years without prolonging life.
LDL Dogma Challenged
Copied to clipboard!
(00:42:17)
  • Key Takeaway: LDL cholesterol loses its significance as a heart disease predictor when corrected for triglycerides and HDL, and observational data suggests higher LDL is inversely associated with all-cause mortality in people over 60.
  • Summary: Framingham study data summarized by William Castelli showed LDL was useless as a predictor unless extremely high, especially after correcting for other lipids. Furthermore, studies indicate that for older adults, lower cholesterol correlates with increased mortality, likely due to cholesterol’s vital role in the immune system and hormone production. Heart disease is fundamentally an inflammatory and metabolic problem, not just a plumbing issue.
Physician Resistance to Change
Copied to clipboard!
(00:52:31)
  • Key Takeaway: Physicians often adhere to established dogma because changing one’s mind is emotionally traumatic, and they lack the time to cut through biased evidence, allowing commercial interests to maintain control over medical education.
  • Summary: The majority of doctors, though well-intentioned, do not realize medical knowledge is under commercial control, leading them to follow biased information. Economist John Kenneth Galbraith noted that people prefer proving their existing beliefs correct over changing their minds. This psychological barrier, combined with the time constraints of practice, prevents the widespread adoption of new, evidence-based paradigms like focusing on inflammation over LDL.
Critique of Statin Research Reporting
Copied to clipboard!
(01:15:40)
  • Key Takeaway: Statin trial results often underreport side effects by using a pre-randomization run-in phase to exclude non-compliant patients who experience early adverse effects.
  • Summary: Statin trial results often underestimate side effects because drug companies control trial design, sometimes removing thousands of patients during a run-in phase due to non-compliance (side effects) before the official trial begins. This practice leads to massively under-reported adverse events in published literature. Furthermore, independent studies often cannot access the raw data to independently verify side effect tracking.
Regulatory Capture and Conflicts of Interest
Copied to clipboard!
(01:18:49)
  • Key Takeaway: Regulatory bodies like the FDA and MHRA rely heavily on funding from the pharmaceutical industry, compromising their ability to independently scrutinize drug data.
  • Summary: The FDA receives 65% of its funding from Big Pharma, and the UK’s MHRA receives 86%, creating a conflict where regulators are hesitant to challenge industry findings. Pharmaceutical companies often provide curated summaries of clinical study reports to the FDA, which the agency tends to trust without reanalyzing the raw data. This financial capture contributes to the continued recommendation of statins for primary prevention despite evidence concerns.
Commercial Determinants of Health
Copied to clipboard!
(01:20:07)
  • Key Takeaway: Commercial determinants of health refer to private sector strategies that promote choices detrimental to public health, often driven by corporate entities like pharma and food companies.
  • Summary: The concept of ‘Commercial Determinants of Health’ describes how multinational corporations subvert public health for privatized profits, exemplified by the American Heart Association receiving $192 million annually from food and pharma companies. Dr. Malhotra suggests that the business practices of these large corporations meet the criteria for psychopathy: callous unconcern for others’ safety and repeated lying for profit.
Food as Precise Medicine
Copied to clipboard!
(01:24:19)
  • Key Takeaway: Food acts as a precise medicine requiring knowledge of pharmacology, dose, frequency, and duration, offering positive side effects like improved energy and sleep, unlike many chronic disease drugs.
  • Summary: Food is not merely a ‘hippy-dippy’ concept but a precise tool containing thousands of molecules that regulate biology, requiring the same nuanced understanding as prescribing medication. Lifestyle changes, unlike pills for chronic disease, generally improve quality of life by increasing energy, improving sleep, and reducing depression. The positive side effects of dietary intervention are substantial and contribute directly to overall well-being.